Advantage

• A refined production platform

  The company possesses advanced production equipment and technology, enabling it to efficiently produce high-quality products.

• Increase investment in technological research and development

  We attach great importance to technological innovation, continuously increase R&D investment, establish a high-quality technical R&D team, and actively collaborate with universities, CR0, and other research institutions to ensure the innovation and competitiveness of our products.

• Industrial chain extension

  Through the integration of upstream and downstream industrial chains, a comprehensive supply chain system has been established, effectively reducing costs and enhancing the market competitiveness of enterprises.

• Pursuit of market share

  Actively expand the market, pursue a leading position in the target market, and enhance market control through the growth of market share.

• Quality management system

  The company has obtained the cGMP quality management system certification, ensuring the safety, effectiveness, and controllability of its products.

• Safety management system

  In accordance with national safety management laws and regulations, a set of strict safety management systems and operating procedures have been established, equipped with advanced safety detection equipment and emergency response facilities. Systematic risk assessments have been conducted, and targeted preventive measures have been formulated to reduce the likelihood of accidents and mitigate potential safety risks.

• Environmental management system

  In accordance with national laws and regulations on ecological environment management, we have established standardized environmental protection management systems and operating procedures. Through continuous technological innovation and the adoption of green processes, we achieve green and clean production. We invest in the construction of efficient environmental protection facilities such as wastewater treatment stations and exhaust gas treatment facilities, ensuring that emissions meet or exceed national emission standards.

• Production workshop layout

  The first phase of the project, with an investment of 150 million yuan, involves local technical renovation of the existing equipment and facilities in workshops 101 and 102, as well as auxiliary buildings, to form a production workshop capable of producing 1,200 tons of pharmaceutical intermediates such as levofloxacin carboxylic acid, ofloxacin carboxylic acid, moxifloxacin, and pefloxacin.
  

  The second phase of the project, with an investment of 350 million yuan, has successfully established two GMP workshops and an independent hydrogenation workshop, capable of meeting various needs such as acylation, amination, cyclization, condensation, hydrolysis, hydrogenation, reduction, and cyanation. Currently, the company boasts a high-end manufacturing platform for active pharmaceutical ingredient (API) CMO/CDMO, with production lines for annual output of hundreds of tons of small molecule targeted anti-tumor drug APIs and their intermediates, as well as production lines for thousands of tons of APIs and advanced intermediates for cardiovascular, antidepressant, antiviral, and other drugs.

• Reaction Type

  Reactions such as nitration, hydrogenation, etherification, methylation, acylation, esterification, saponification, reduction, cyclization, bromination, chlorination, condensation, substitution, addition, hydrolysis, deprotection, salification, silyl etherification, and cleavage, with reaction temperatures ranging from -70°C to 300°C.